March 2, 2007
Management shake-up at Sepracor
By Christina Davis
Marlboro-based drug maker Sepracor Inc. has appointed Adrian Adams president and COO to replace W. James O'Shea, who has stepped into the newly created position of vice chairman of the company.
Adams was president and CEO of Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion.
Separately, the Sepracor board elected Andrew Koven to the newly created position of executive vice president, general counsel and secretary. Koven held a similar position at Kos Pharmaceuticals from 2003 to 2007.
The pharmaceutical firm is best known for its sleeping pill Lunesta.
Adams was president and CEO of Kos Pharmaceuticals from 2002 until the acquisition of the company by Abbott Laboratories in December 2006 for $3.7 billion.
Separately, the Sepracor board elected Andrew Koven to the newly created position of executive vice president, general counsel and secretary. Koven held a similar position at Kos Pharmaceuticals from 2003 to 2007.
The pharmaceutical firm is best known for its sleeping pill Lunesta.
WBJ Web Partners
Most Recent
Most Recent
0 Comments